Saluda Medical
Saluda Medical (SLD) is a publicly traded Spinal & Peripheral Interfaces company founded in 2013 and based in Bloomington, United States.
Develops closed-loop, dose-control neuromodulation for chronic pain. Its FDA-approved Evoke System is the first spinal cord stimulation (SCS) device to record the spinal cord's physiologic response to stimulation via Evoked Compound Action Potentials (ECAPs) and automatically adjust stimulation in real time to maintain a targeted level of neural activation. Spun out of Australia's NICTA research centre in 2013. Raised a US$150M Series F in April 2023 (led by Wellington Management) and a US$100M financing in January 2025 (led by Redmile Group). Listed on the ASX (ticker SLD) on 5 December 2025, raising A$230.8M (~US$150M). At 36 months the company reports 83% of patients achieving at least 50% pain reduction with zero explants due to loss of efficacy.
The first commercially approved closed-loop, sensing-based neurostimulator, validating ECAP feedback as a measurable, dose-controlled standard for neuromodulation and giving the BCI grid an independent, publicly traded peripheral/spinal-interface leader.
saludamedical.com ↗·Spinal & Peripheral Interfaces·
United States·public · SLD 
